A clinical observation of escitalopram  and  venlafaxine-extended-release (XR) general in  the treatment of outpatients with depression

Abstract

Abstract: AIM: To observe and compare the efficacy and safety of escitalopram and venlafaxine-extended-release (XR) in the treatment of outpatients with depression. METHODS: 89 outpatients with depression were randomized to receive escitalopram or venlafaxine-extended-release (XR) for 8 weeks, and dose titrated from 10 mg/d or 75 mg/d to a maximum of 20 mg/d or 150 mg/d respectively within the first 2 weeks of treatment. Effects and adverse events were evaluated with MADRS, HAMA, CGI and TESS before and after the treatment. RESULTS: After 8 weeks treatment, total scores of MADRS of 39 patients with escitalopram or 36 venlafaxine-XR both showed significant change compared with baseline, and escitalopram. After 8 weeks treatment, percentage of recovery were 51.28% and 44.44% respectively, while significant improvement percentage were 71.79% and 61.11% in each group. CONCLUSION: Escitalopram and venlafaxine-extended-release (XR) both are effective and safe antidepressants, and escitalopram has a faster and better effectiveness profile in treatment of depression.

Key words: Escitalopram, Venlafaxine-extended-release, Depression, Efficacy, Safety

CLC Number:

R749

WANG He-qiu, REN Zhi-bin, WANG Shu-zhen. A clinical observation of escitalopram and venlafaxine-extended-release (XR) general in the treatment of outpatients with depression[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1174-1178.

References

[1] Chen F, Larsen MB, Sánchez C,et al.The S-enantiomer of R,S-Citalopram,increases inhibitor binding to the human serotonin transporter by an allosteric mechanism.Comparison with other serotonin transporter inhibitors[J]. Eur Neuropsychopharmacol,2005,15(2):193-198.
[2] Wellington K, Perry CM. Venlafaxin-ER : a review of its use in the man agement major depression [J]. CNS Drugs,2001,15(8):643-669.
[3] Thase ME, Entsuah AR,Rudolph RL. Remission rats during treatment with venlafaxine or selective serotonin reuptake inhibitors[J]. Br J Psychiatry, 2001,178:234-241.
[4] Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram Versus citalopram:the surprising role of the R-enantiomer[J].Psychopharmacology, 2004, 174(2):163-176.
[5] Mentgonmery SA, Huuson AKT, Bothmer J. A randomized study comparing escitalopram with venlafaxineXR inpatients in primary care with major depressive disorder[J]. Neuropsychobiology, 2004,50(1):57-64.
[6] 顾牛范,李华芳,舒良,等.文拉法辛缓释剂治疗抑郁的双盲,随机平行、对照、多中心临床研究[J].中国新药与临床杂志,2002,21(2):66-71.
[7] Wade A, Friis Andersen H. The onset of effect for escitalopram and its relevance for chinical management of depression[J].Curr Med Res Opin,2006,122(11):2010-2110.
[8] Norman TR, Leonard BE. Fast-acting antidepressants:Can the Need be Met[J] ？ CNS Drugs, 1994,2(2):120-131.
[9] Posternak MA, Zimmerman M. Is there a delay in the antidepressanteffect? A meta-analysis[J]. J Clin Psychiatry, 2005,66(2):148-158.
[10] Kaspera S, Spadone C, Verpillat P, et al. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis[J]. Int Clin Psychopharmacol,2006, 21(2):105-110.
[11] Kasper S, de Swart H, Andersen HF. Escitalopram in the treatment of depressed elderly patients[J]. Am J Geriatr Psychiatry ,2005,13 (10):884-891.
[12] Kennedy SH, Andersen HF, Thase ME. Thase. Escitalopram in the treatment of major depressive disorder: A meta-analysis[J]. Curr Med Res Opin, 2009,25(1):161-175.
[13] 朱毅平,金学敏.艾司西酞普兰联合左旋甲状腺素钠治疗抑郁症伴发亚临床甲状腺功能减退33例[J]. 医药导报,2010,29(9):1154-1156.

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[3]	ZHANG Taotao, SU Wenxiu, TIAN Limin. Research progress on the relationship between subclinical hypothyroidism and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 954-960.
[4]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[5]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[6]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[7]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[8]	HE Teng, XU Xiangyang, XU Xiangqing, LIU Cunming, YANG Chun. Ketamine for depression treatment: past, present, and future [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1125-1132.
[9]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[10]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[11]	WANG Yeqing, WANG Yuhong, LIU Jian, ZHAO Hongqing, ZOU Manshu. Research progress of relevance between cholecystokinin and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 672-679.
[12]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[13]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[14]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[15]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.

A clinical observation of escitalopram and venlafaxine-extended-release (XR) general in the treatment of outpatients with depression

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments